drugset
drugset / Trial / NCT03954600

A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

NCT03954600 ↗

Phase 1 Completed 49 enrolled Neuropore Therapies Inc. Celerion · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the PK, safety and tolerability of orally administered NPT520-34 in healthy subjects at single and multiple doses that may be therapeutically relevant.

Timeline

Start
2019-05-05
Primary completion
2019-10-02
Completion
2019-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject NPT520-34 Unknown 125 mg Oral

Indications

No indication recorded.